These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 20496207)

  • 1. Establishing bioequivalence in complete and incomplete data designs using AUCs.
    Jaki T; Wolfsegger MJ; Lawo JP
    J Biopharm Stat; 2010 Jul; 20(4):803-20. PubMed ID: 20496207
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Establishing bioequivalence in serial sacrifice designs.
    Wolfsegger MJ
    J Pharmacokinet Pharmacodyn; 2007 Feb; 34(1):103-13. PubMed ID: 17053981
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Estimation of AUC from 0 to Infinity in Serial Sacrifice Designs.
    Wolfsegger MJ; Jaki T
    J Pharmacokinet Pharmacodyn; 2005 Dec; 32(5-6):757-66. PubMed ID: 16328101
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Confidence intervals for ratios of AUCs in the case of serial sampling: a comparison of seven methods.
    Jaki T; Wolfsegger MJ; Ploner M
    Pharm Stat; 2009; 8(1):12-24. PubMed ID: 18407562
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estimation in AB/BA crossover trials with application to bioequivalence studies with incomplete and complete data designs.
    Jaki T; Pallmann P; Wolfsegger MJ
    Stat Med; 2013 Dec; 32(30):5469-83. PubMed ID: 23801551
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-compartmental estimation of pharmacokinetic parameters in serial sampling designs.
    Wolfsegger MJ; Jaki T
    J Pharmacokinet Pharmacodyn; 2009 Oct; 36(5):479-94. PubMed ID: 19847629
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design and inference for 3-stage bioequivalence testing with serial sampling data.
    Yan F; Zhu H; Liu J; Jiang L; Huang X
    Pharm Stat; 2018 Sep; 17(5):458-476. PubMed ID: 29726096
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sample size calculation for the Power Model for dose proportionality studies.
    Sethuraman VS; Leonov S; Squassante L; Mitchell TR; Hale MD
    Pharm Stat; 2007; 6(1):35-41. PubMed ID: 17323313
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Power Analysis and Sample Size Determination for Crossover Trials with Application to Bioequivalence Assessment of Topical Ophthalmic Drugs Using Serial Sampling Pharmacokinetic Data.
    Yu YP; Yan XY; Yao C; Xia JL
    Biomed Environ Sci; 2019 Aug; 32(8):614-623. PubMed ID: 31488237
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of bioequivalence of highly variable drugs using clinical trial simulations. II: Comparison of single and multiple-dose trials using AUC and Cmax.
    el-Tahtawy AA; Tozer TN; Harrison F; Lesko L; Williams R
    Pharm Res; 1998 Jan; 15(1):98-104. PubMed ID: 9487554
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of truncated area under the curve on failed bioequivalence studies: a computer simulation analysis.
    Mahmood I
    Drug Metabol Drug Interact; 2004; 20(1-2):77-83. PubMed ID: 15283304
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The duration of measuring partial AUCs for the assessment of bioequivalence.
    Endrenyi L; Csizmadia F; Tothfalusi L; Balch AH; Chen ML
    Pharm Res; 1998 Mar; 15(3):399-404. PubMed ID: 9563068
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Truncated areas under the curve in the assessment of pioglitazone bioequivalence. Data from a single-center, single-dose, randomized, open-label, 2-way cross-over bioequivalence study of two formulations of pioglitazone 45 mg tablets under fasting conditions.
    Almeida S; Filipe A; Neves R; Pinho C; Pedroso P; Castillo A; Trabelsi F
    Arzneimittelforschung; 2011; 61(1):32-9. PubMed ID: 21355444
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An extension of Satterthwaite's approximation applied to pharmacokinetics.
    Nedelman JR; Jia X
    J Biopharm Stat; 1998 May; 8(2):317-28. PubMed ID: 9598425
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bioequivalence evaluation of sparse sampling pharmacokinetics data using bootstrap resampling method.
    Shen M; Machado SG
    J Biopharm Stat; 2017; 27(2):257-264. PubMed ID: 27906608
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bioequivalence study of two different tablet formulations of donepezil using truncated areas under the curve. A single-center, single-dose, randomized, open-label, 2-way crossover study under fasting conditions.
    Almeida S; Filipe A; Neves R; Desjardins I; Shink E; Castillo A
    Arzneimittelforschung; 2010; 60(3):116-23. PubMed ID: 20422942
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Non-traditional study designs to demonstrate average bioequivalence for highly variable drug products.
    Patterson SD; Zariffa NM; Montague TH; Howland K
    Eur J Clin Pharmacol; 2001 Nov; 57(9):663-70. PubMed ID: 11791897
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Statistical aspects of bioequivalence testing between two medicinal products.
    Zintzaras E
    Eur J Drug Metab Pharmacokinet; 2005; 30(1-2):41-6. PubMed ID: 16010860
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The use of truncated area under the curves in the bioequivalence evaluation of long half-life drugs. Studies with donepezil and memantine.
    Erkent U; Koytchev R
    Arzneimittelforschung; 2008; 58(5):255-8. PubMed ID: 18589560
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of the upper sample size limit in two-stage bioequivalence designs.
    Karalis V
    Int J Pharm; 2013 Nov; 456(1):87-94. PubMed ID: 23954235
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.